← FDA DRUG APPROVALS

FDA ANDA · ANDA203102

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATE

Sponsor: PADDOCK LLC

APPLICATION
ANDA203102
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
None (Tentative Approval)

Products

MAGNESIUM SULFATE ANHYDROUS; POTASSIUM SULFATE; SODIUM SULFATENone (Tentative Approval)
MAGNESIUM SULFATE ANHYDROUS 1.6GM/BOT, POTASSIUM SULFATE 3.13GM/BOT, SODIUM SULFATE 17.5GM/BOT · SOLUTION · ORAL

Approval history

2016-08-18UNKNOWN · Original — Letter ↗TA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →